Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arbutus Biopharma Corp ABUS

Healthcare Biotechnology
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.


NDAQ:ABUS - Post by User

Arbutus Biopharma Corp
Bullboard Posts
User Avatar Image
(34)
•••
Post by grover11on Sep 22, 2014 6:11pm
157 Views
Post# 22960072

Dr. Sacra confirms he received TKM-EBOLA

Dr. Sacra confirms he received TKM-EBOLA

Dr. Sacra confirms he received TKM-EBOLA

 
BN 09/22 22:04 *SACRA MAY BE WELL ENOUGH TO LEAVE UNIT SOON, DOCTOR SAYS
BN 09/22 22:00 *EBOLA PATIENT SACRA GOT TKM-EBOLA FOR 7 DAYS
BFW 09/22 21:59 *EBOLA PATIENT SACRA’S DOCTORS CONFIRM TREATED WITH TKM-EBOLA
BN 09/22 21:59 *EBOLA PATIENT SACRA DOCTORS: TKM-EBOLA MADE BY TEKMIRA PHARMA
BN 09/22 21:59 *EBOLA PATIENT SACRA DOCTORS CONFIRM TREATED WITH TKM-EBOLA

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities